Last reviewed · How we verify
Test 1 Montelukast
At a glance
| Generic name | Test 1 Montelukast |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects (NA)
- Establishment of a Diagnosis and Treatment System for Information Processing Damage in Children With OSAHS
- Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions (PHASE1)
- PK and Safety Study of HCP1102, HGP0813 and HGP1408 (PHASE1)
- Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects (PHASE1)
- Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions (PHASE1)
- Comparison of the Effects of Nasal Steroids and Montelukast on Olfactory Functions in Patients With Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test 1 Montelukast CI brief — competitive landscape report
- Test 1 Montelukast updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI